229 articles
Solithromycin
Solithromycin (CEM-101, T-4288) is a fluoroketolide, fourth-generation macrolide antibiotic with three ribosomal binding sites, developed for pneumonia and gonorrhea; US and EU development halted in 2016-2017 over liver-safety concerns, with an NDA filed in Japan.
Spiramycin
Spiramycin (Rovamycin) is a 16-membered macrolide antibiotic from Streptomyces ambofaciens, isolated in France in 1954. Used against gram-positive bacteria and to prevent congenital toxoplasmosis in pregnancy; not commercially available in the US.
Standard triple therapy
Standard triple therapy is a Helicobacter pylori eradication regimen combining a proton pump inhibitor with amoxicillin and clarithromycin twice daily, now recommended only where clarithromycin resistance is low.
Streptomycin
Streptomycin, a 1944 aminoglycoside from Streptomyces griseus and the first antibiotic effective against tuberculosis, now a second-line injectable TB and endocarditis drug dosed 15 mg/kg IM, limited by ototoxicity and rrs/gidB resistance.
Sudoterb
Sudoterb (LL 3858, LL-3858) is an orally active pyrrole anti-tuberculosis drug candidate developed by India's Lupin Ltd; MIC90 0.25 µg/mL, unknown mechanism, reached Phase IIa trials in India, development inactive.
Sulbactam-durlobactam
Sulbactam-durlobactam (XACDURO) is a co-packaged IV antibiotic for HABP/VABP from susceptible Acinetobacter baumannii-calcoaceticus complex; FDA-approved May 2023, IDSA-preferred for CRAB with a carbapenem, non-inferior to colistin in ATTACK.
Sulfabenzamide
Sulfabenzamide (CAS 127-71-9) is a synthetic sulfonamide antibacterial, FDA approved 1945, that inhibits bacterial dihydropteroate synthase. Used mainly in the discontinued triple-sulfa vaginal cream with sulfathiazole and sulfacetamide.
Sulfacarbamide
Sulfacarbamide (sulfanilylurea, Urosulfan), CAS 547-44-4, is a withdrawn sulfonamide anti-infective introduced in the 1940s for bacterial infections; Germany withdrew it in 1992 over a negative benefit/risk ratio.
Sulfacetamide
Sulfacetamide (sodium sulfacetamide, Sodium Sulamyd) is a sulfonamide antibiotic used as a 10% ophthalmic solution for bacterial conjunctivitis and, with sulfur, topically for acne, rosacea, and seborrheic dermatitis.
Sulfacytine
Sulfacytine (Renoquid, CAS 17784-12-2) is a short-acting sulfonamide antibiotic, a PABA analog inhibiting dihydropteroate synthetase, taken orally for urinary tract infections; FDA approved 1975, now discontinued.
Sulfadiazine
Sulfadiazine is a short-acting sulfonamide antibiotic introduced in 1941 that blocks folic acid synthesis in bacteria and is combined with pyrimethamine as standard therapy for toxoplasmosis.
Sulfadicramide
Sulfadicramide (Irgamid, sulfirgamide; INN sulfadicramidum) is a sulfanilamide sulfonamide anti-infective, CAS 115-68-4, C11H14N2O3S, ATC S01AB03, used as a 15% ophthalmic ointment in some countries.
Sulfaguanidine
Sulfaguanidine (Sulgin, CAS 57-67-0) is a poorly absorbed sulfonamide intestinal antiinfective (ATC A07AB03, DDD 4 g oral) introduced in 1941 for bacillary dysentery, now mostly veterinary, DHPS/PABA-antifolate mechanism.
Sulfalene
Sulfalene (sulfamethopyrazine, Kelfizine) is a long-acting sulfonamide antibiotic (ATC J01ED02, half-life about 65 h) used for respiratory and urinary infections and, with pyrimethamine as Metakelfin, for falciparum malaria, mainly in the Indian subcontinent.
Sulfamerazine
Sulfamerazine is a sulfonamide antibacterial drug, the monomethyl derivative of sulfadiazine, introduced in 1942 and no longer used in human medicine while retaining limited veterinary uses.
Sulfameter
Sulfameter (sulfamethoxydiazine, sulfametoxydiazine, brand Sulla) is a long-acting sulfonamide antibiotic, ATC J01ED04, DDD 0.5 g oral, formerly used for urinary tract infections and leprosy; first approved 1966, now discontinued.
Sulfamethizole
Sulfamethizole (Thiosulfil, Urolucosil) is a short-acting sulfonamide antibiotic, CAS 144-82-1, that inhibits bacterial dihydropteroate synthase and was used mainly for urinary tract infections; no longer marketed in the US.
Sulfamethoxazole
Sulfamethoxazole, a sulfonamide antibiotic (Bactrim with trimethoprim, co-trimoxazole), inhibits DHPS in bacterial folate synthesis; used for Pneumocystis pneumonia, shigellosis, and urinary tract infections.
Sulfamethoxypyridazine
Sulfamethoxypyridazine (Lederkyn, Kynex, Midicel) is a long-acting sulfanilamide sulfonamide antibiotic, N1-(6-methoxy-3-pyridazinyl)sulfanilamide, introduced 1956-1957, half-life 37 h, dihydropteroate synthetase inhibitor, now largely withdrawn.
Sulfanilamide
Sulfanilamide is a synthetic sulfonamide antibacterial drug identified in 1935 as the active agent behind the dye Prontosil, and its 1937 toxic elixir formulation killed over 100 people.
Sulfisomidine
Sulfisomidine (sulfaisodimidine, Elkosin) is a short-acting sulfonamide antibacterial, CAS 515-64-0, formula C12H14N4O2S, ATC J01EB01, studied for urinary tract infections in the 1950s and now withdrawn.
Sulfisoxazole
Sulfisoxazole is a synthetic sulfonamide antibiotic that stops bacterial growth, available in the United States only combined with erythromycin, prescribed mainly for bacterial ear infections in children.
Sulfonamide (medicine)
Sulfonamide (medicine): sulfa drugs, the oldest synthetic antibacterial class, PABA analogues inhibiting bacterial DHPS; includes sulfamethoxazole, TMP-SMX, sulfadoxine-pyrimethamine; distinguished from non-antibiotic sulfonamides like furosemide and celecoxib, which lack cross-reactivity.
Sulopenem
Sulopenem is a thiopenem β-lactam antibiotic, approved in the United States in 2024 as ORLYNVAH to treat uncomplicated urinary tract infections, with activity against ESBL-producing bacteria.
Surotomycin
Surotomycin (CB-183,315), a daptomycin-analog cyclic lipopeptide antibiotic for Clostridium difficile infection; membrane-disrupting, minimally absorbed; Phase 3 trials showed no benefit over vancomycin and development was discontinued.
Taniborbactam
Taniborbactam (VNRX-5133), Venatorx's bicyclic boronate beta-lactamase inhibitor, inhibits all four Ambler beta-lactamase classes including NDM/VIM metallo-enzymes; combined with cefepime, it beat meropenem in the CERTAIN-1 phase 3 cUTI trial and is under FDA review after a 2024 complete response letter.
Tebipenem pivoxil
Tebipenem pivoxil (Utebzi) is an oral prodrug of the carbapenem tebipenem, FDA-approved June 17, 2026 as the first oral carbapenem, for complicated urinary tract infections including pyelonephritis in adults with limited oral options; notable for carnitine-depletion risk.
Tedizolid
Tedizolid (torezolid, TR-700; prodrug tedizolid phosphate, Sivextro) is a second-generation oxazolidinone antibiotic for ABSSSI, 200 mg once daily for 6 days, more potent than linezolid and active against cfr linezolid-resistant strains.
Telavancin
Telavancin (Vibativ, TD-6424) is a semisynthetic lipoglycopeptide antibiotic derived from vancomycin, FDA-approved in 2009 for complicated skin infections and 2013 for pneumonia, with dual cell wall and membrane action and nephrotoxicity risk.
Telithromycin
Telithromycin (Ketek), the first ketolide antibiotic, derived from macrolides, treated community-acquired respiratory infections at 800 mg once daily. Withdrawn from the EU in 2019 and unavailable in the US after hepatotoxicity and myasthenia gravis warnings.